Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

ED Mellins, C Macaubas, AA Grom - Nature Reviews Rheumatology, 2011 - nature.com
ED Mellins, C Macaubas, AA Grom
Nature Reviews Rheumatology, 2011nature.com
Systemic juvenile idiopathic arthritis (sJIA) has long been recognized as unique among
childhood arthritides, because of its distinctive clinical and epidemiological features,
including an association with macrophage activation syndrome. Here, we summarize
research into sJIA pathogenesis. The triggers of disease are unknown, although infections
are suspects. Once initiated, sJIA seems to be driven by innate proinflammatory cytokines.
Endogenous Toll-like receptor ligands, including S100 proteins, probably synergize with …
Abstract
Systemic juvenile idiopathic arthritis (sJIA) has long been recognized as unique among childhood arthritides, because of its distinctive clinical and epidemiological features, including an association with macrophage activation syndrome. Here, we summarize research into sJIA pathogenesis. The triggers of disease are unknown, although infections are suspects. Once initiated, sJIA seems to be driven by innate proinflammatory cytokines. Endogenous Toll-like receptor ligands, including S100 proteins, probably synergize with cytokines to perpetuate inflammation. These and other findings support the hypothesis that sJIA is an autoinflammatory condition. Indeed, IL-1 is implicated as a pivotal cytokine, but the source of excess IL-1 activity remains obscure and the role of IL-1 in chronic arthritis is less clear. Another hypothesis is that a form of hemophagocytic lymphohistiocytosis underlies sJIA, with varying degrees of its expression across the spectrum of disease. Alternatively, sJIA with MAS might be a genetically distinct subtype. Yet another hypothesis proposes that inadequate downregulation of immune activation is central to sJIA, supporting evidence for which includes 'alternative activation' of monocyte and macrophages and possible deficiencies in IL-10 and T regulatory cells. Some altered immune phenotypes persist during clinically inactive disease, which suggests that this stage might represent compensated inflammation. Despite much progress being made, many questions remain, providing fertile ground for future research.
nature.com